Archives

Enhanced (NYSE: ENHA) to Build AI-Native Technology Within its Live Enhanced Consumer Platform with Rezolve Ai (NASDAQ: RZLV) in Multi-Million Dollar Strategic Partnership

B Rezolve Ai technology to power Live Enhanced platform to accelerate scaling and efficiency Rezolve Ai to serve as official AI technology partner of The… Login to continue reading Login…

Read MoreEnhanced (NYSE: ENHA) to Build AI-Native Technology Within its Live Enhanced Consumer Platform with Rezolve Ai (NASDAQ: RZLV) in Multi-Million Dollar Strategic Partnership

Pending Class Action Lawsuit Involving the Purchase and/or Acquisition of Evolv Technologies Holdings, Inc. Common Stock Between June 28, 2021 and October 25, 2024

B BOSTON, May 18, 2026 /PRNewswire/ —  UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS IN RE EVOLV TECHNOLOGIES HOLDINGS INC. SECURITIES LITIGATION Case No. 1:24-cv-10761-ADB… Login to continue reading Login…

Read MorePending Class Action Lawsuit Involving the Purchase and/or Acquisition of Evolv Technologies Holdings, Inc. Common Stock Between June 28, 2021 and October 25, 2024

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

B GUANGZHOU, China, May 18, 2026 /PRNewswire/ — Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord… Login to continue reading Login…

Read MoreBio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States